
Sign up to save your podcasts
Or


Friday, May 8, 2026 - Week 19
CURE SYNGAP1 STRATEGY WORKING
Our strategy has always been to derisk SYNGAP1 so that industry will invest and bring their skill and capital to bear. We leverage donor dollars to maximize impact. Yesterday was a great example:
EARNINGS REPORTS
CAMP4 1Q26 Results: $99M https://investors.camp4tx.com/news-releases/news-release-details/camp4-reports-first-quarter-2026-financial-results-and-corporate
We submitted our first regulatory filing for CMP-002 in Australia which positions us to initiate a global first-in-human Phase 1/2 clinical trial in the second half of 2026.
Stoke 1Q26 Results: $411M https://investor.stoketherapeutics.com/news-releases/news-release-details/stoke-therapeutics-announces-first-quarter-2026-financial
Lead optimization is underway to identify a clinical candidate for the treatment of SYNGAP1 in 2026. SYNGAP1 is a severe and rare genetic neurodevelopmental disease.
Praxis 1Q26 Results: $1.4B https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-19
Praxis remains on track to nominate a development candidate for each of its three early stage ASO therapeutic initiatives in the first half of 2026: PRAX-090 is designed to address SYNGAP1 loss-of-function (LoF) mutations, a leading cause of severe intellectual disability and epilepsy in DEEs.
#CompetitionIsGoodForThePatient
KCNT1 Big Day today - Congratulations
Post: https://www.linkedin.com/posts/graglia_kcnt1-share-7458560855744618496-X10d
Press Release: https://www.linkedin.com/posts/kcnt1-kcnt1-epilepsy-ugcPost-7458487179149787136-kH7c/
WATCH & SHARE OUR VIDEO
Watch and share the new SYNGAP1 Video, it is excellent and helps explain our cause to families and friends. We need to turn them into supporters and donors.
cureSYNGAP1.org/SYNGAP1 -> https://youtu.be/pO3ayASBiEk
INAUGURAL SF NIGHT OF IMPACT, CA – 20 days
Join us this is our only Gala for 2026!
cureSYNGAP1.org/SF26
5TH SCRAMBLE FOR SYNGAP, SC – 148 days
Classic case of a small event becoming an institution!
cureSYNGAP1.org/Scramble26
USA: use your ICD-10, F78.A1: https://onlinelibrary.wiley.com/doi/10.1002/epi.70142
PUBMED
Pubmed 2026 is at 28. +9 vs the week. (61 last year was +9) https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2026-2026&sort=date
https://pubmed.ncbi.nlm.nih.gov/42093631/ ADHD in patients with #DLG2 #NRXN1 #SHANK3 #SYNGAP1
SOCIAL MATTERS
4,940 LinkedIn. https://www.linkedin.com/company/curesyngap1
1,569 YouTube. https://www.youtube.com/@CureSYNGAP1
11.1k Twitter https://twitter.com/cureSYNGAP1
45k Insta https://www.instagram.com/curesyngap1
$CAMP closed at $4.46. https://www.google.com/finance/beta/quote/CAMP:NASDAQ
$STOK closed at $32.89. https://www.google.com/finance/beta/quote/STOK:NASDAQ
$ACAD closed at $22.40. https://www.google.com/finance/beta/quote/ACAD:NASDAQ
$PRAX closed at $330.02. https://www.google.com/finance/beta/quote/PRAX:NASDAQ
Like and subscribe to this podcast wherever you listen. https://curesyngap1.org/podcasts/syngap10
Episode 207 of #Syngap10 #SYNGAP1 #CureSYNGAP1 #Podcast #PatientAdvocacy
By Syngap Research Fund, 501(c)(3)5
8585 ratings
Friday, May 8, 2026 - Week 19
CURE SYNGAP1 STRATEGY WORKING
Our strategy has always been to derisk SYNGAP1 so that industry will invest and bring their skill and capital to bear. We leverage donor dollars to maximize impact. Yesterday was a great example:
EARNINGS REPORTS
CAMP4 1Q26 Results: $99M https://investors.camp4tx.com/news-releases/news-release-details/camp4-reports-first-quarter-2026-financial-results-and-corporate
We submitted our first regulatory filing for CMP-002 in Australia which positions us to initiate a global first-in-human Phase 1/2 clinical trial in the second half of 2026.
Stoke 1Q26 Results: $411M https://investor.stoketherapeutics.com/news-releases/news-release-details/stoke-therapeutics-announces-first-quarter-2026-financial
Lead optimization is underway to identify a clinical candidate for the treatment of SYNGAP1 in 2026. SYNGAP1 is a severe and rare genetic neurodevelopmental disease.
Praxis 1Q26 Results: $1.4B https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-19
Praxis remains on track to nominate a development candidate for each of its three early stage ASO therapeutic initiatives in the first half of 2026: PRAX-090 is designed to address SYNGAP1 loss-of-function (LoF) mutations, a leading cause of severe intellectual disability and epilepsy in DEEs.
#CompetitionIsGoodForThePatient
KCNT1 Big Day today - Congratulations
Post: https://www.linkedin.com/posts/graglia_kcnt1-share-7458560855744618496-X10d
Press Release: https://www.linkedin.com/posts/kcnt1-kcnt1-epilepsy-ugcPost-7458487179149787136-kH7c/
WATCH & SHARE OUR VIDEO
Watch and share the new SYNGAP1 Video, it is excellent and helps explain our cause to families and friends. We need to turn them into supporters and donors.
cureSYNGAP1.org/SYNGAP1 -> https://youtu.be/pO3ayASBiEk
INAUGURAL SF NIGHT OF IMPACT, CA – 20 days
Join us this is our only Gala for 2026!
cureSYNGAP1.org/SF26
5TH SCRAMBLE FOR SYNGAP, SC – 148 days
Classic case of a small event becoming an institution!
cureSYNGAP1.org/Scramble26
USA: use your ICD-10, F78.A1: https://onlinelibrary.wiley.com/doi/10.1002/epi.70142
PUBMED
Pubmed 2026 is at 28. +9 vs the week. (61 last year was +9) https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2026-2026&sort=date
https://pubmed.ncbi.nlm.nih.gov/42093631/ ADHD in patients with #DLG2 #NRXN1 #SHANK3 #SYNGAP1
SOCIAL MATTERS
4,940 LinkedIn. https://www.linkedin.com/company/curesyngap1
1,569 YouTube. https://www.youtube.com/@CureSYNGAP1
11.1k Twitter https://twitter.com/cureSYNGAP1
45k Insta https://www.instagram.com/curesyngap1
$CAMP closed at $4.46. https://www.google.com/finance/beta/quote/CAMP:NASDAQ
$STOK closed at $32.89. https://www.google.com/finance/beta/quote/STOK:NASDAQ
$ACAD closed at $22.40. https://www.google.com/finance/beta/quote/ACAD:NASDAQ
$PRAX closed at $330.02. https://www.google.com/finance/beta/quote/PRAX:NASDAQ
Like and subscribe to this podcast wherever you listen. https://curesyngap1.org/podcasts/syngap10
Episode 207 of #Syngap10 #SYNGAP1 #CureSYNGAP1 #Podcast #PatientAdvocacy

69,626 Listeners

29 Listeners

19 Listeners